PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
Visit https://www.peervoice.com/MJW860 to view the entire programme with slides. After completing “Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions”, participants will be able to: Summarise the recent advances in the treatment for patients with newly diagnosed secondary acute myeloid leukaemia (sAML); Describe which patient- and disease-related factors need to be considered when selecting an induction therapy for patients with newly diagnosed sAML; and Identify the right induction treatment approach for individual patients with sAML based on patient- and disease-related factors.